These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32703358)

  • 1. Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma.
    Qureshi ZM; Qamar S
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):662-664. PubMed ID: 32703358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity.
    Saeed S; Rauf F; Iqbal F; Khan AS; Khan AH; Alamgeer R
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4039-4045. PubMed ID: 36579984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of programmed death-ligand 1 protein expression between primary tumors and lymph node metastatic lesions in oral squamous cell carcinoma].
    Xia RH; Hu YH; Zhang CY; Xu SM; Li J
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2022 Nov; 57(11):1113-1118. PubMed ID: 36379889
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.
    Nocini R; Vianini M; Girolami I; Calabrese L; Scarpa A; Martini M; Morbini P; Marletta S; Brunelli M; Molteni G; Parwani A; Pantanowitz L; Eccher A
    Clin Exp Dent Res; 2022 Jun; 8(3):690-698. PubMed ID: 35593124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of PD-1/PD-L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma.
    Xu SB; Wang MY; Shi XZ; Wang Q; Yu M; Zhang W; Xu XH; Liu LK
    Oral Dis; 2023 Nov; 29(8):3268-3277. PubMed ID: 35921211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
    He J; Chen XF; Xu MG; Zhao J
    Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference between Keratinized- and Non-Keratinized-Originating Epithelium in the Process of Immune Escape of Oral Squamous Cell Carcinoma.
    Kitsukawa Y; Fukumoto C; Hyodo T; Komiyama Y; Shiraishi R; Koike A; Yagisawa S; Kunitomi Y; Hasegawa T; Kotani W; Ishida K; Wakui T; Kawamata H
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
    Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
    PeerJ; 2023; 11():e15922. PubMed ID: 37663280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and PD-L1 expression in oral squamous cell carcinoma.
    Chiu HW; Lin CH; Lee HH; Lu HW; Lin YK; Lin YF; Lee HL
    Clin Immunol; 2024 Feb; 259():109892. PubMed ID: 38185269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
    Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
    Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
    Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma.
    Ko HH; Peng HH; Cheng AN; Chou HE; Hou HH; Kuo WT; Liu WW; Kuo MY; Lee AY; Cheng SJ
    Cancer Sci; 2023 Oct; 114(10):3857-3872. PubMed ID: 37525561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
    Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
    Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma].
    Chen ZH; Wu YD
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2020 Aug; 38(4):449-453. PubMed ID: 32865367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
    Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
    Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
    Lenouvel D; González-Moles MÁ; Ruiz-Ávila I; Gonzalez-Ruiz L; Gonzalez-Ruiz I; Ramos-García P
    Oral Oncol; 2020 Jul; 106():104722. PubMed ID: 32330687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.